OCEANIA: real-world study of ovarian cancer treatment patterns across multiple lines of therapy in Argentina and Brazil.

Autor:	Soares C; GSK, Rio de Janeiro, Brazil., Abreu G; GSK, Rio de Janeiro, Brazil., Nogueira da Silva TL; GSK, Rio de Janeiro, Brazil., Queiroz J; GSK, Rio de Janeiro, Brazil., Menezes P; GSK, Rio de Janeiro, Brazil., Bernardino G; GSK, Rio de Janeiro, Brazil., Pires T; GSK, Rio de Janeiro, Brazil., Carrizo M; GSK, Buenos Aires, Argentina., Felice R; GSK, Buenos Aires, Argentina., Riggi MC; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Cravero F; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Ribeiro de Souza ALA; Orizon, Barueri City, São Paulo, Brazil., Jotimliansky L; GSK, Buenos Aires, Argentina.
Jazyk:	angličtina
Zdroj:	Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (27), pp. 2023-2036. Date of Electronic Publication: 2024 May 29.
DOI:	10.1080/14796694.2024.2343650
Abstrakt:	Aim: To evaluate real-world data on treatment patterns in Argentina and Brazil in patients with ovarian cancer. Methods: This study evaluated de-identified antineoplastic exposure data from a private healthcare provider in Argentina and health claims database (Orizon) in Brazil from 2010 to 2019 and 2015 to 2020, respectively. Results: Platinum-based chemotherapy was the most common first-line therapy (Argentina: n =311 [87.6%]; Brazil: n = 1142 [79.3%]). The proportion of patients receiving platinum-based chemotherapy declined across both populations from first- to second-line, while use of non-platinum-based, targeted, and hormone therapies increased. Duration of platinum-based treatment and time to next treatment decreased from first- to fourth-line. Conclusion: There is an unmet need for effective therapies that can prolong time to next treatment in ovarian cancer in Argentina and Brazil.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu